Unicycive Therapeutics (UNCY) Stock Price, Quote, News & History | Benzinga

SPY778.07−0.00%QQQ743.63−0.32%BTC/USD83,273.10+1.88%DIA516.00−0.37%GLD381.53−0.16%TLT78.33+0.36%

Unicycive Therapeutics Inc (UNCY) Stock Price, Quote, News & History

UNCYNASDAQ

Trade with Public

Trade with Public

$3.73

-0.32-7.9%

Last update: Oct 13, 5:24 PM

$3.76

-0.29-7.16%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.99

Close

$3.73

Volume / Avg.

1.84M / 836.38K

Day Range

$3.76 - $3.76

52 Wk Range

3.93 - 8.74

Market Cap

$112.81M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

24

Short Interest

17.83%

Days to Cover

5.74

Recent Unicycive Therapeutics Inc News

Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.

Daragh Thomas

Nasdaq Gains Over 300 Points; Chicago PMI Falls In June

US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%. Tech shares surged, real estate stocks fell. Chicago Business Barometer declined to 56.7.

Avi Kapoor

Why Is Unicycive Therapeutics Stock Falling Tuesday?

Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again over third-party manufacturing issues.

Vandana Singh

US Stocks Mixed; Home Prices Increase 1.1% In April

US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up 0.09%. Edible Garden AG up 87%, Unicycive Therapeutics down 46%.

Avi Kapoor

FDA Raises Manufacturing Concerns, Delays Unicycive's Kidney Disease Drug Approval

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate manufacturer in place.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-27.84M

Investing Cash Flow (TTM)

-17.25M

Financing Cash Flow (TTM)

66.95M

Free Cash Flow (TTM)

-27.85M

Capital Expenditure (TTM)

-9.00K

Net Change in Cash (TTM)

21.86M

Analyst Trends and Forecast

1

May

2

Jun

1

Jul

2

Aug

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$53.80M

PE Ratio (TTM)

-

PE Ratio (FWD)

1.27

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.12

Earnings Yield % (TTM)

-43.21%

Earnings Yield % (FWD)

78.64%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.91

Company Debt

Total Debt

$67.00K

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$44.19M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-